(Q34342498)

1 August 2017

1 reference

title

Strategies for disease modification in Alzheimer's disease (English)

1 reference

1 August 2017

0 references

Martin Citron

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 September 2004

1 reference

Nature Reviews Neuroscience

1 August 2017

published in

1 reference

1 August 2017

1 reference

1 August 2017

1 reference

1 August 2017

page(s)

677-685

1 reference

Evaluation of memantine for the treatment of Alzheimer's disease

1 August 2017

cites work

1 reference

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

31 March 2020

1 reference

Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo

31 March 2020

1 reference

Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss

31 March 2020

1 reference

Drug discovery: a historical perspective

31 March 2020

1 reference

Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice.

31 March 2020

1 reference

Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial

31 March 2020

1 reference

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

31 March 2020

1 reference

A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

31 March 2020

1 reference

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

31 March 2020

1 reference

Antibody-mediated resolution of light chain-associated amyloid deposits.

31 March 2020

1 reference

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

31 March 2020

1 reference

Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease.

31 March 2020

1 reference

Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology

31 March 2020

1 reference

Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy.

31 March 2020

1 reference

Cerebral hemorrhage after passive anti-Abeta immunotherapy

31 March 2020

1 reference

Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology

31 March 2020

1 reference

Immunization against Alzheimer's beta -amyloid plaques via EFRH phage administration

31 March 2020

1 reference

Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease

31 March 2020

1 reference

Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model

31 March 2020

1 reference

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

31 March 2020

1 reference

Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.

31 March 2020

1 reference

Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease

31 March 2020

1 reference

Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease

31 March 2020

1 reference

Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors

31 March 2020

1 reference

Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor

31 March 2020

1 reference

Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease

31 March 2020

1 reference

Amyloid beta-peptide is produced by cultured cells during normal metabolism

31 March 2020

1 reference

Production of the Alzheimer amyloid beta protein by normal proteolytic processing

31 March 2020

1 reference

Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain

31 March 2020

1 reference

The gamma-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester reduces A beta levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice

31 March 2020

1 reference

Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex

31 March 2020

1 reference

Reconstitution of gamma-secretase activity

31 March 2020

1 reference

A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain

31 March 2020

1 reference

Gamma -secretase inhibitors repress thymocyte development

31 March 2020

1 reference

Presenilin-dependent gamma-secretase activity modulates thymocyte development

31 March 2020

1 reference

Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation

31 March 2020

1 reference

The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease

31 March 2020

1 reference

A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity

31 March 2020

1 reference

The non-cyclooxygenase targets of non-steroidal anti-inflammatory drugs, lipoxygenases, peroxisome proliferator-activated receptor, inhibitor of kappa B kinase, and NF kappa B, do not reduce amyloid beta 42 production

31 March 2020

1 reference

Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity

31 March 2020

1 reference

Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity

31 March 2020

1 reference

Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE

31 March 2020

1 reference

Purification and cloning of amyloid precursor protein beta-secretase from human brain

31 March 2020

1 reference

Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity

31 March 2020

1 reference

Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase

31 March 2020

1 reference

Beta-secretase inhibition for the treatment of Alzheimer's disease--promise and challenge

31 March 2020

1 reference

Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease

31 March 2020

1 reference

Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease

31 March 2020

1 reference

Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease

31 March 2020

1 reference

Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients

31 March 2020

1 reference

Knockouts model the 100 best-selling drugs--will they model the next 100?

31 March 2020

1 reference

Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation

31 March 2020

1 reference

BACE1 is the major beta-secretase for generation of Abeta peptides by neurons

31 March 2020

1 reference

BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics

31 March 2020

1 reference

Subsite specificity of memapsin 2 (beta-secretase): implications for inhibitor design.

31 March 2020

1 reference

Alzheimer's beta-secretase, beta-site amyloid precursor protein-cleaving enzyme, is responsible for cleavage secretion of a Golgi-resident sialyltransferase

31 March 2020

1 reference

Characterization of alpha 2,6-sialyltransferase cleavage by Alzheimer's beta -secretase (BACE1).

31 March 2020

1 reference

The cell adhesion protein P-selectin glycoprotein ligand-1 is a substrate for the aspartyl protease BACE1.

31 March 2020

1 reference

BACE1 (beta-secretase) knockout mice do not acquire compensatory gene expression changes or develop neural lesions over time

31 March 2020

1 reference

BACE1 (beta-secretase) transgenic and knockout mice: identification of neurochemical deficits and behavioral changes

31 March 2020

1 reference

Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice

31 March 2020

1 reference

BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease

31 March 2020

1 reference

Human β-Secretase (BACE) and BACE Inhibitors

31 March 2020

1 reference

Protease inhibitors: current status and future prospects

31 March 2020

1 reference

Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor

31 March 2020

1 reference

Inflammation, autotoxicity and Alzheimer disease

31 March 2020

1 reference

Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies

31 March 2020

1 reference

Clinical trial of indomethacin in Alzheimer's disease.

31 March 2020

1 reference

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial

31 March 2020

1 reference

Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease.

31 March 2020

1 reference

Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease.

31 March 2020

1 reference

Statins and the risk of dementia

31 March 2020

1 reference

Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.

31 March 2020

1 reference

Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families

31 March 2020

1 reference

Cholesterol and the biology of Alzheimer's disease.

31 March 2020

1 reference

Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide

31 March 2020

1 reference

How do statins control neuroinflammation?

31 March 2020

1 reference

Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease

31 March 2020

1 reference

Reappraising neurotransmitter-based strategies

31 March 2020

1 reference

Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease

31 March 2020

1 reference

Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease

31 March 2020

1 reference

Neurodegenerative tauopathies: human disease and transgenic mouse models

31 March 2020

1 reference

Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein

31 March 2020

1 reference

Cdk5 is a key factor in tau aggregation and tangle formation in vivo

31 March 2020

1 reference

Amyloid deposition as the central event in the aetiology of Alzheimer's disease

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRN1495

1 reference

Dimensions Publication ID

1 August 2017

1004279783

0 references

1 reference